Canada's new prime minister is triggering an election campaign this weekend. Here’s what to know
Trump has ordered the dismantling of the US Education Department. Here's what that means
Rapper Yella Beezy charged with capital murder in shooting death of rapper Mo3
Most LAX – Heathrow flights cancelled as London airport closes after blaze
Hegseth to visit the Philippines for talks that will include South China Sea concerns, envoy says
Texas measles outbreak expected to last for months, though vaccinations are up from last year
A NASA spacecraft will make another close pass of the sun
NYC will eventually have to abandon part of its water supply if it keeps getting saltier
Tobacco Road is front and center of March Madness with 3 women's sites and men's site in area
By Ludwig Burger
FRANKFURT (Reuters) -Bayer said on Wednesday its Nubeqa drug was shown to slow the progression of a certain type of prostate cancer in a late-stage trial, underpinning growth prospects for one of the German drugmaker's key pharmaceutical products.
Bayer is developing Nubeqa, also known as darolutamide, jointly with Finland's Orion. The drug is already approved in other prostate cancer treatment settings.
Bayer said in a statement that Nubeqa, when combined with androgen deprivation therapy, significantly prolonged progression-free survival when compared with androgen deprivation therapy alone in a phase III trail.
Trial participants suffered from a type of metastatic prostate cancer that responds to hormone therapy.
Details of the trial would be presented at an as yet undisclosed medical conference, Bayer said, adding that it plans to seek regulatory approval for wider use of the drug.
(Reporting by Ludwig Burger, Editing by Rachel More)
